FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 36th Annual Roth Conference.
| Event | 36th Annual Roth Conference |
| Date | March 19, 2024 |
| Time | 8:00 AM Pacific Time (11:00 AM Eastern Time) |
| Link | /webcast/roth48/register.aspx?conf=roth48&page=nvct&url=https://wsw.com/webcast/roth48/nvct/1852019 |
About Nuvectis Pharma
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. The U.S. Food and Drug Administration granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma. NXP900 is a novel, small molecule SRC/YES1 kinase inhibitor currently undergoing a Phase 1a dose escalation study.
For more information, please visit www.nuvectis.com.
Nuvectis Pharma Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations Contact
Christopher M. Calabrese
LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$8.20 |
| Daily Change: | -0.08 -0.97 |
| Daily Volume: | 37,887 |
| Market Cap: | US$171.300M |
April 29, 2025 March 26, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
